Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Lōkahi Therapeutics™ Initiates Clinical Trial Manufacturing for LT-100

25 August 2026 · By · Wire by Fusion42

Published

25 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at biospace.com →

◆ Verified

Fusion42 · 26 August 2026 · Fusion42 review

Lōkahi Therapeutics has started GMP manufacturing for LT-100, a pure honeybee venom biologic targeting osteoarthritis pain, moving towards a single subcutaneous injection dosing in upcoming clinical trials.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You need to start preparing for a shift towards patient-friendly osteoarthritis treatments as Lōkahi moves from complex multi-injection regimens to a single injection. This opens a door to non-opioid, biologic pain therapies that could displace older methods.

◆ Coverage

1 source · 25 Aug 2026

◆ Related on Wire

◆ Topics

Biotechclinical-trialmanufacturingosteoarthritisbiologicnon-opioid-treatment